Personalis (NASDAQ:PSNL) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded Personalis from “strong sell” to “hold.” The broader analyst consensus is also “Hold,” with a consensus price target of $14.54.
• Personalis shares opened at $16.60 and were down 3.5%, while the stock’s 12-month range is $4.95 to $18.89. The company recently missed quarterly EPS expectations, reporting a loss of $0.30 per share, though revenue of $22.36 million exceeded forecasts.
• Insiders sold 256,233 shares worth approximately $3.57 million over the past 90 days, including a 100,000-share sale by the CEO. Hedge funds and other institutional investors own 61.91% of the company.

Personalis (NASDAQ:PSNL - Get Free Report) was upgraded by equities research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued on Monday, Zacks reports.

PSNL has been the topic of a number of other research reports. Lake Street Capital downgraded Personalis from a "buy" rating to a "hold" rating and set a $16.25 target price on the stock. in a report on Monday, July 20th. BTIG Research boosted their price target on Personalis from $11.00 to $16.25 and gave the company a "buy" rating in a research note on Monday, July 20th. Craig Hallum lowered shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 price target for the company. in a research report on Monday, August 24th. Morgan Stanley increased their price objective on shares of Personalis from $9.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 9th. Finally, Needham & Company LLC downgraded shares of Personalis from a "buy" rating to a "hold" rating in a report on Monday, July 20th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $14.54.

Personalis Trading Down 3.5%

NASDAQ:PSNL opened at $16.60 on Monday. Personalis has a 12 month low of $4.95 and a 12 month high of $18.89. The company has a market cap of $1.74 billion, a PE ratio of -15.23 and a beta of 2.31. The company has a 50 day simple moving average of $14.68 and a two-hundred day simple moving average of $10.41.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Research analysts forecast that Personalis will post -1.07 earnings per share for the current year.

Insider Transactions at Personalis

In related news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares of the company's stock, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This represents a 2.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 256,233 shares of company stock valued at $3,568,236. Company insiders own 4.20% of the company's stock.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. Deutsche Bank AG increased its stake in Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company's stock worth $309,000 after buying an additional 1,655 shares in the last quarter. Royal Bank of Canada increased its stake in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after buying an additional 2,395 shares in the last quarter. Howland Capital Management LLC raised its holdings in Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company's stock valued at $1,872,000 after acquiring an additional 2,500 shares during the period. Finally, Intech Investment Management LLC raised its holdings in Personalis by 23.4% during the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company's stock valued at $162,000 after acquiring an additional 3,851 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.